Synthesis of combretastatin analogs: Evaluation of in vitro anticancer activity and molecular docking studies

Medicinal Chemistry Research

Volumn 21, Issue 11, 2012, Pages 3720-3729

  Kumar, Sunil ^a   Sapra, Sameer ^a   Kumar, Raj ^a   Gupta, Manish Kumar ^a   Koul, Surrinder ^b   Kour, Tandeep ^b   Saxena, Ajit Kumar ^b   Suri, Om Prakash ^a   Dhar, Kanahya Lal ^a  

^a ISF COLLEGE OF PHARMACY   (India)

^b CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Anticancer; Combretastatin; Molecular docking; Phenyl acetic acid; Tubulin inhibitor

Indexed keywords

2,3 DIPHENYL PROP 2 ENOIC ACID; 2,5 DIPHENYLPENTA 2,4 DIENOIC ACID; 3 (2 ACETOXYPHENYL) 2 PHENYL PROP 2ENOIC ACID; 3 (2 CHLOROPHENYL) 2 PHENYL ACRYLIC ACID; 3 (2 NITROPHENYL) 2 PHENYL PROP 2 ENOIC ACID; 3 (2,3 DIHYDROXYPHENYL) 2 PHENYL PROP 2ENOIC ACID; 3 (2,3 DIMETHOXYPHENYL) 2 PHENYL PROP 2 ENOIC ACID; 3 (2,3,4 TRIMETHOXYPHENYL) 2 PHENY PROP 2ENOIC ACID; 3 (2,4,5 TRIMETHOXYPHENYL) 2 PHENYL PROP 2 ENOIC ACID; 3 (2,5 DIMETHOXYPHENYL) 2 PHENYL PROP 2 ENOIC ACID; 3 (3 CHLOROPHENYL) 2 PHENYL PROP 2ENOIC ACID; 3 (3 HYDROXY 4 METHOXYPHENY) 2 PHENYL PROP 2 ENOIC ACID; 3 (3,4 METHYLENEDIOXYPHENYL) 2 PHENYL PROP 2 ENOIC ACID; 3 (3,4,5 TRIMETHOXYPHENYL) 2 PHENY PROP 2 ENOIC ACID; 3 (4 CHLOROPHENYL) 2 PHENYL PROP 2ENOIC ACID; 3 (NAPHTHALENE 5YL) 2 PHENYL PROP 2 ENOIC ACID; ACETIC ACID; ANTINEOPLASTIC AGENT; COMBRETASTATIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CENTRAL NERVOUS SYSTEM TUMOR; COLON CANCER; CONCENTRATION RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; LUNG CANCER; MOLECULAR DOCKING; OVARY CANCER; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; SUBSTITUTION REACTION; X RAY CRYSTALLOGRAPHY;

EID: 84871439768     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9887-7     Document Type: Article

References (26)

1. Bellina F, Cauteruccio S, Monti S, Rossi R (2006) Novel imidazolebased combretastatin A-4 analogues: evaluation of their in vitro antitumor activity and molecular modelling study of their binding to the colchicine site of tubulin. Bioorg Med Chem Lett 16:5757-5762
2. Brown RT, Fox BW, Hadfield JA, McGown AT, Mayalarp SP, Pettit GR, Woods JA (1995) Synthesis of water-soluble sugar derivatives of combretastatin A-4. J Chem Soc Perkin Trans 1:577-582
3. ChemDraw Ultra 6.0 and Chem3D Ultra (2000) Cambridge Soft Corporation, Cambridge
4. Cushman MS, Layfayette W, Hamel E, Bethesda (1995) Stilbene derivatives as anticancer agents. United States Patent. Patent no 5,430,062
5. Ducki S, Mackenzie G, Greedy B, Armitage S, Chabert JF, Bennett E, Nettles J, Snyder JP, Lawrence NJ (2009) Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-Aryl chalcones. Bioorg Med Chem 17:7711-7722
6. Furst R, Zupko I, Berenyi A, Ecker GF, Rinner U (2009) Synthesis and antitumor-evaluation of cyclopropyl-containing combretastatin analogs. Bioorg Med Chem Lett 19:6948-6951
7. GOLD (2009) Evaluation version 4.0.1. Cambridge Crystallographic Data Centre, Cambridge
8. Hadfield JA, Ducki S, Hirst N, McGown AT (2003) Tubulin and microtubules as targets for anticancer drugs. Prog Cell Cycle Res 5:309-325
9. Kaffy J, Pontikis R, Carrz D, Croisy A, Monneret C, Florent JC (2006) Isoxazole-type derivatives related to combretastatin A-4, synthesis and biological evaluation. Bioorg Med Chem 14:4067-4077
10. Kong Y, Grembecka J, Edler MC, Hamel E, Mooberry SL, Sabat M, Rieger J, Brown ML (2005) Structure-based discovery of a boronic acid bioisostere of combretastatin A-4. Chem Biol 12:1007-1014
11. Lee L, Davis R, Vanderham J, Hills P, Mackay H, Brown T, Mooberry SL, Lee M (2008) 1,2,3,4-Tetrahydro-2-thioxopyrimidine analogs of combretastatin-A4. Eur J Med Chem 43:2011-2015
12. Liou JP, Chang YL, Kuo FM, Chang CW, Tseng HY, Wang CC, Yang YN, Chang JY, Lee SJ, Hsieh HP (2004) Concise synthesis and structure-Activity relationship of combretastatin A-4 analogues, 1-Aroylindoles, as novel classes of potent antitubulin agents. J Med Chem 47:4247-4257
13. Liou JP, Wu ZY, Kuo CC, Chang CY, Lu PY, Chen CM, Hsieh HP, Chang JY (2008) Discovery of 4-Amino and 4-hydroxy-1-Aroylindoles as potent tubulin polymerization inhibitors. J Med Chem 51:4351-4355
14. McGown AT, Fox BW (1989) Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. Anticancer Drug Des 3:249-254
15. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757-766
16. Nandy P, Banerjee S, Gao H, Hui MB, Lien EJ (1991) Quantitative structure-Activity relationship analysis of combretastatins: A class of novel antimitotic agents. Pharm Res 8:776-781
17. Ouyang X, Piatnitski EL, Pattaropong V, Chen X, He HY, Kiselyov AS, Valankar A, Kwakami J, Labelle M, Smith L, Lohman J, Lee SP, Malikzay A, Fleming J, Gerlak J, Wang Y, Rosler RL, Zhou K, Mitelman S, Camara M, Surguladze D, Boody JF, Tuma MC (2006) Oxadiazole derivatives as a novel class of antimitotic agents: synthesis, inhibition of tubulin polymerization and activity in tumor cell lines. Bioorg Med Chem Lett 16:1191-1196
18. Pettit GR, Singh SB, Niven ML, Hamel E, Schmit JM (1987) Isolation, structure and synthesis of combretastatin A-1 and B-, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 50:119-120
19. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M (2004) Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428:198-202
20. Shewach DS, Kuchta RD (2009) Introduction to cancer chemotherapeutics. Chem Rev 109:2859-2861
21. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112
22. Stokvis E, Nan-Offeringa L, Ouwehand M, Tibben MM, Rosing H, Schnaar Y, Grigat M, Romeis P, Schellens JTM, Beijnen JH (2004) Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry. Cancer Treat Rev 18:1465-1471
23. The Merck Index (2006) Fourteenth edition, Organic Name Reactions-324
24. Tron GC, Pirali T, Sorba G, Pagliai F, Busacca S, Genazzani AA (2006) Medicinal chemistry of combretastatin A4: present and future directions. J Med Chem 49:3033-3044
25. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais VH, Zhu Z, Hicklin DJ, Bohlen P, Chaplin DJ, May C, Raffi SJ (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signalling. Clin Investig 115:2992
26. Woods JA, Hadfield JA, Pettit GR, Fox BW, McGown AT (1995) The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer 71:705-711